ESC 365 - Pulmonary hypertension due to left heart disease should be treated with drugs approved for idiopathic pulmonary arterial hypertension - PRO

ESC Premium Access

Pulmonary hypertension due to left heart disease should be treated with drugs approved for idiopathic pulmonary arterial hypertension - PRO

Session: Controversies in the management of pulmonary hypertension and venous thromboembolism

Topic: Treatment

Speaker: Professor S. Rosenkranz (Cologne, DE)

Event: ESC Congress 2019

Congress Presentation

Add to my library

About the speaker

Professor Stephan Rosenkranz

Heart Center at the University of Cologne, Cologne (Germany)

29 presentations

9 followers

5 more presentations in this session

Lifelong anticoagulation is the best option after unprovoked venous thromboembolism - PRO

Speaker: Professor L. Mazzolai (Lausanne, CH)

Lifelong anticoagulation is the best option after unprovoked venous thromboembolism - CON

Speaker: Professor N. Meneveau (Besancon, FR)

Lifelong anticoagulation is the best option after unprovoked venous thromboembolism - Discussion

Pulmonary hypertension due to left heart disease should be treated with drugs approved for idiopathic pulmonary arterial hypertension - CON

Speaker: Doctor J. Bermejo Thomas (Madrid, ES)

Pulmonary hypertension due to left heart disease should be treated with drugs approved for idiopathic pulmonary arterial hypertension - Discussion

Access the full session

Controversies in the management of pulmonary hypertension and venous thromboembolism

Speakers: Professor S. Rosenkranz, Professor L. Mazzolai, Professor N. Meneveau, Doctor J. Bermejo Thomas

About the event

ESC Congress 2019

31 August - 4 September 2019

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources